Hedy Kindler
· Associate Dean of Clinical Science Research, Human Subjects Professor of MedicineUniversity of Chicago · Hematology and Blood and Marrow Transplantation
Active 1950–2025
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Hedy Kindler, MD, is a Professor of Medicine and Associate Dean of Clinical Science Research at the University of Chicago. Her clinical interests focus on gastrointestinal stromal tumors (GIST) and mesothelioma. Dr. Kindler has contributed extensively to the understanding and management of mesothelioma, including the development of consensus guidelines for its treatment and management. Her research encompasses immune composition and immunotherapy outcomes in mesothelioma, as well as the application of radiomics and convolutional neural networks for diagnosis and segmentation of mesothelioma. She is actively involved in advancing clinical practices and research in thoracic and peritoneal mesothelioma, with a focus on improving patient outcomes through multidisciplinary approaches.
Research topics
- Medicine
- Oncology
- Internal medicine
- Data Mining
- Computer Science
- Biology
- Pathology
- Nanotechnology
- Materials science
- Computational biology
Selected publications
The Lancet Oncology · 2020 · 2454 citations
Journal of Clinical Oncology · 2020 · 390 citations
PURPOSE: + PDAC. PATIENTS AND METHODS: intravenously on days 3 and 10; treatment for patients in arm B was the same as that for patients in arm A, and arm A also received veliparib 80 mg orally twice per day on days 1 to 12 cycled every 3 weeks. The primary end point was RRs of arm A and arm B evaluated separately using a Simon two-stage design. Secondary end points were progression-free survival, DCR, OS, safety, and correlative analyses. RESULTS: = .6). Two-year OS rate for the entire cohort w…
Journal of Clinical Oncology · 2022 · 130 citations
PURPOSE: -paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). METHODS: ) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles. The primary end point was independently assessed disease-free survival (DFS). Additional end points included investigator-assessed DFS, overall survival (OS), and safety. RESULTS: -paclitaxel + gemcitabine) and 68% (gemcitabine) of patients experienc…
Cancer Discovery · 2020 · 68 citations
Senior authorCorresponding.
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Journal of Clinical Oncology · 2025-01-08 · 45 citations
article1st authorCorrespondingASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary us…
Recent grants
NIH · $3.7M · 2019–2026
NCI National Clinical Trials Network-Network Lead Academic Participating Sites
NIH · $3.2M · 2014–2019
NIH · $6.7M · 2015
Frequent coauthors
- 273 shared
Richard M. Goldberg
Applied Physical Sciences (United States)
- 235 shared
Donna Niedzwiecki
Duke University
- 228 shared
Federico Innocenti
University of North Carolina at Chapel Hill
- 226 shared
Kouros Owzar
Duke University
- 225 shared
Alan P. Venook
- 213 shared
Herbert I. Hurwitz
Duke University
- 205 shared
Mary F. Mulcahy
Northwestern Medicine
- 197 shared
Eileen M. O’Reilly
Memorial Sloan Kettering Cancer Center
Similar researchers at University of Chicago
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Hedy Kindler
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup